Lilly, Resilience to invest $750 million in US drug manufacturing expansion

July 30 (Reuters) - Drugmaker Eli Lilly and privately held contract manufacturer Resilience will invest $750 million ‌to expand pharmaceutical manufacturing capacity in the ‌U.S. and strengthen the domestic medicine supply chain, Resilience said on ​Thursday.

Global drugmakers have been ramping up U.S. manufacturing since last year and stockpiling inventory as President Donald Trump's administration moves to impose 100% tariffs on branded ‌drugs unless companies ⁠cut prices or make medicines domestically.

• Resilience said the investment will increase the production ⁠of critical medicines and create 400 new high-skilled jobs in the Cincinnati, Ohio region.

• The company's manufacturing ​operations in ​the region will now ​include Lilly's KwikPen injectable ‌device for treating diabetes and obesity, it added.

• The multi-year manufacturing partnership between Lilly and Resilience, which began in 2023, has already produced more than 150 million doses of medicines for U.S. patients in ‌vial and pre-filled syringe formats, ​according to Resilience.

• Lilly's manufacturing ​head Edgardo Hernandez ​said the partnership reflects the drugmaker's ‌efforts to meet rising demand ​for its medicines.

• ​Lilly's U.S. capital expansion commitments since 2020 total more than $55 billion and it plans to ​break ground on ‌several of its recently announced U.S. manufacturing ​sites this year.

(Reporting by Christy Santhosh in Bengaluru; ​Editing by Jonathan Ananda)